Abstract Prizes 2009

[f]Abstract Prizes 2009[/f] [u][f]Clinical Research[/f][/u] J. Ardill, et al, Belfast, United Kingdom. Assessment of the sensitivity of circulating neurokinin A and chromogranin A to changing prognosis in patients with serotonin-producing endocrine tumors of the ileum and colon A. Astudillo, et al, Oviedo, Spain. Snail as epithelial-mesenchymal transition marker in neuroendocrine tumors of the lung [f]R. Bettini, et al, Verona, Italy. Non-functioning pancreatic endocrine tumors: Any correlation of tumor size with malignancy?[/f] P. Brown, et al, The Woodlands, TX, USA. LX1032: A novel approach for managing gastrointestinal symptoms in carcinoid syndrome A. Falchetti, et al, Florence, Italy. Early identification of the MEN1-associated gastrinomas: Use of the secretin test in the experience of the Center for Hereditary Endocrine Tumors of Florence, Italy P. Ferolla, et al, Perugia, Italy. Prevalence and features of MEN1 in a large cohort of gastroenteropancreatic and thoracic NET: Data from a large multicentric Italian database L. Krolicki, et al, Warsaw, Poland. Clinical results of PRRT with 90Y-DOTA TATE and 90Y/177Lu-DOTATATE - what is better for therapy? T. Meyer, et al, London, United Kingdom. Chemotherapy with 5-Fluorouracil, cisplatin and streptozocin (FCiSt) for neuroendocrine tumors A. Rinke, et al, Marburg, Germany. Placebo-controlled, double-blind, prospective, randomized study on the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group [f]J. Strosberg, et al, Tampa, FL, USA. First line treatment of metastatic pancreatic endocrine carcinomas with capecitabine and temozolomide[/f] [u][f]Basic/Translational Research[/f][/u] A. Couvelard, et al, Clichy, France. Molecular predictors of response to chemotherapy in advanced/metastatic gastroenteropancreatic endocrine tumors [f]A. Kalhan, et al, Cardiff, United Kingdom. Adenosine A2 receptor signalling mediates chromogranin A secretion from neuroendocrine tumors[/f] [f]M. Mei, et al, Beijing, China. Dual expression of α-internexin in pancreatic endocrine tumors and its implications[/f] [center] *** [/center] [color=]Two other abstract authors, each who presented their work in poster format at the Granada conference, also received monetary awards for their work:[/color] [f]P. Szybinski, et al, Cracow, Poland[/f]: [k]Colorectal neuroendocrine tumors of the gastroenteropancreatic tract (GEP-NET) - minimal invasive surgery[/k] [k]Radio-guided surgery for the intraoperative detection of neuroendocrine tumors of the gastroenteropancreatic tract (GEP-NET)[/k] [f]V. Prasad, et al, Bad Berka, Germany[/f]: [k]Impact of Peptide Receptor Radionuclide Therapy using Y-90 DOTA-TATE/Lu-177 DOTA-TATE on renal tubular function: Long-term follow-up Management of neuroendocrine tumors of the rectum (rNET) using Ga-68 somatostatin receptor PET/CT (SR-PET/CT) and Peptide Receptor Radionuclide Therapy (PRRT) Pancreatic neuroendocrine tumor (pNET): Survival benefits and efficacy of Peptide Receptor Radionuclide Therapy (PRRT) using Y-90/Lu-177 DOTA-TATE Peptide Receptor Radionuclide Therapy (PRRT) of neuroendocrine tumor patients with carcinoid heart disease[/k]
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.